New treatments targeting epigenetic changes in Alzheimer's disease
New epigenetic inhibitors for Alzheimer's disease treatment
['FUNDING_R01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-11116902
This study is looking for new tiny molecules that can help block a specific enzyme to potentially improve memory and thinking skills in people with Alzheimer's disease by changing how certain genes work.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11116902 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new small molecules that inhibit a specific enzyme (HDAC11) to potentially treat Alzheimer's disease. By modifying the epigenetic regulation of genes, the researchers aim to create compounds that can improve cognitive function in preclinical models of Alzheimer's. The project involves identifying and testing these compounds to find the most effective candidates for further development into drugs. If successful, this approach could lead to innovative therapies that address the underlying mechanisms of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options for patients suffering from Alzheimer's disease, potentially improving their cognitive function and quality of life.
How similar studies have performed: Previous research has shown promise in using epigenetic approaches to treat neurological diseases, suggesting that this method could be a viable avenue for Alzheimer's treatment.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, CHANGNING — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: WANG, CHANGNING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia